^
    3years
    Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. (PubMed, Sci Rep)
    In addition, the drug combination decreased phosphorylated ERK level, indicating inhibition of the mitogenic signaling pathway MEK/ERK. Taken together, the resminostat plus sorafenib combination counteracts platelet-mediated cancer promoting effects in HCC cells.
    Journal • Combination therapy • Epigenetic controller
    |
    CD44 (CD44 Molecule)
    |
    CD44 expression
    |
    sorafenib • Kinselby (resminostat)
    3years
    Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma. (PubMed, PLoS One)
    The JAKi/HDACi combination exhibited substantial anti-tumor effects in CTCL cell lines, and may represent a promising novel therapeutic modality for CTCL patients.
    Journal
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    Jakafi (ruxolitinib) • Kinselby (resminostat)
    over3years
    Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism. (PubMed, J Med Invest)
    In comparison with PC-9 cells, PC-9 BIMi2- / - cells were less sensitive to apoptosis mediated by EGFR-TKIs such as gefitinib and osimertinib. Invest. 67 : 343-350, August, 2020.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • BCL2L11 deletion
    |
    Tagrisso (osimertinib) • gefitinib • Kinselby (resminostat)